Based on the Ionis Pharmaceuticals Inc stock forecast from 13 analysts, the average analyst target price for Ionis Pharmaceuticals Inc is USD 56.70 over the next 12 months. Ionis Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ionis Pharmaceuticals Inc is Bearish, which is based on 3 positive signals and 9 negative signals. At the last closing, Ionis Pharmaceuticals Inc’s stock price was USD 29.10. Ionis Pharmaceuticals Inc’s stock price has changed by +2.65% over the past week, -11.58% over the past month and -30.45% over the last year.
No recent analyst target price found for Ionis Pharmaceuticals Inc
No recent average analyst rating found for Ionis Pharmaceuticals Inc
Company Overview Ionis Pharmaceuticals Inc
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California. Read Less
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the trea...Read More
Frequently Asked Questions About Ionis Pharmaceuticals Inc (IONS) Stock
Based on ratings from 13 analysts Ionis Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 13 buy, sell and 7 hold ratings.
Unfortunately we do not have enough data on IONS's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for IONS is USD 56.70 over the next 12 months. The maximum analyst target price is USD 75 while the minimum anlayst target price is USD 38.
IONS stock's Price/Earning ratio is 524.14.
Our analysis grades IONS stock's Price / Earning ratio at F. This means that IONS stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this IONS may be a overvalued for its sector.
The last closing price of IONS's stock was USD 29.10.
The most recent market capitalization for IONS is USD 4.95B.
Based on targets from 13 analysts, the average taret price for IONS is projected at USD 56.70 over the next 12 months.
This means that IONS's stock price may go up by +94.85% over the next 12 months.
We can't find any ETFs which contains Ionis Pharmaceuticals Inc's stock.
As per our most recent records Ionis Pharmaceuticals Inc has 1,069 Employees.
Ionis Pharmaceuticals Inc's registered address is 2855 Gazelle Court, Carlsbad, CA, United States, 92010.
You can get more information about it from Ionis Pharmaceuticals Inc's website at https://www.ionis.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Ionis Pharmaceuticals Inc (IONS) Stock
Based on ratings from 13 analysts Ionis Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 13 buy, sell and 7 hold ratings.
Unfortunately we do not have enough data on IONS's stock to indicate if its a good dividend stock.
Based on targets from 13 analysts, the average taret price for IONS is USD 56.70 over the next 12 months. The maximum analyst target price is USD 75 while the minimum anlayst target price is USD 38.
IONS stock's Price/Earning ratio is 524.14.
Our analysis grades IONS stock's Price / Earning ratio at F. This means that IONS stock's Price/Earning ratio is above 99% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this IONS may be a overvalued for its sector.
The last closing price of IONS's stock was USD 29.10.
The most recent market capitalization for IONS is USD 4.95B.
Based on targets from 13 analysts, the average taret price for IONS is projected at USD 56.70 over the next 12 months.
This means that IONS's stock price may go up by +94.85% over the next 12 months.
We can't find any ETFs which contains Ionis Pharmaceuticals Inc's stock.
As per our most recent records Ionis Pharmaceuticals Inc has 1,069 Employees.
Ionis Pharmaceuticals Inc's registered address is 2855 Gazelle Court, Carlsbad, CA, United States, 92010.
You can get more information about it from Ionis Pharmaceuticals Inc's website at https://www.ionis.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IONS !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
